PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells

Cancer Investigation

Volumn 32, Issue 7, 2014, Pages 339-348

  Gangopadhyay, Nupur N ^a   Luketich, James D ^a   Opest, Amy ^a   Landreneau, Rodney ^b   Schuchert, Matthew J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

Author keywords

Lung cancer; Signal transduction; Therapy

Indexed keywords

CASPASE 3; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

LUNG CANCER; SIGNAL TRANSDUCTION; THERAPY;

APOPTOSIS; CASPASE 3; CASPASE 9; CELL PROLIFERATION; CYTOCHROMES C; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 84903994994     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.919303     Document Type: Article

References (40)

1. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005;52(1): 109-118. (Pubitemid 40725605)
2. Mark L, Katona A, Deli L. An attempt to evaluate the risk factors related to coronary heart disease in Hungary. Cor Vasa 1991;33(4): 265-272.
3. Ta LE, Schmelzer JD, Bieber AJ, Loprinzi CL, Sieck GC, Brederson JD, Low PA, Windebank AJ. A novel and selective poly (ADPribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLo S One 2013;8(1):e54161.
4. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4(5): 421-440. (Pubitemid 40704125)
5. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013;34(6): 1217-1256.
6. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011;10(8): 1192-1199.
7. Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25(1): 32-40.
8. Roux R, Zweifel M, Rustin GJ. Biologicals in the upfront treatment of ovarian cancer: focus on bevacizumab and poly (ADPRibose) polymerase inhibitors. Am Soc Clin Oncol Educ Book 2012;32: 340-344.
9. Lee YR, Yu DS, Liang YC, Huang KF, Chou SJ, Chen TC, Lee CC, Chen CL, Chiou SH, Huang HS. New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules. PLoS One 2013;8(2):e56284.
10. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam- Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013;73(7): 2271-2280.
11. Spigel DR. PARP inhibitors in lung cancer. J Thorac Oncol 2012;7(16 Suppl 5):S392-S393.
12. Nasuno T, Mimaki S, Okamoto M, Esumi H, Tsuchihara K. Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Sci 2014;105(2): 202-210.
13. Sakogawa K, Aoki Y, Misumi K, Hamai Y, Emi M, Hihara J, Shi L, Kono K, Horikoshi Y, Sun J, Ikura T, Okada M, Tashiro S. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition. Cancer Sci 2013;104(12): 1593-1599.
14. Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G. PARP inhibitors in cancer therapy: magic bullets but moving targets. Front Oncol 2013;3:279.
15. Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder- Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia 2013;15(10): 1207-1217.
16. Gangopadhyay NN, Luketich JD, Opest A, Visus C, Meyer EM, Landreneau R, Schuchert MJ. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines. Cancer Invest 2011;29(9): 608-616.
17. Siegfried JM. Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line. J Cell Biochem 1989;41(2): 91-95. (Pubitemid 19277486)
18. Takahashi A, Watanabe T, Mondal A, Suzuki K, Kurusu-Kanno M, Li Z, Yamazaki T, Fujiki H, Suganuma M. Mechanism-based inhibition of cancer metastasis with (-)-epigallocatechin gallate. Biochem Biophys Res Commun 2014;443(1): 1-6.
19. Tian T, Li J, Li B, Wang Y, Li M, Ma D, Wang X. Genistein exhibits anti-cancer effects via down-regulating FoxM1 in H446 small-cell lung cancer cells. Tumour Biol 2014;35(5): 4137-4145.
20. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 2009;16(1): 3-11.
21. Yokosuka T, Goto H, Fujii H, Naruto T, Takeuchi M, Tanoshima R, Kato H, Yanagimachi M, Kajiwara R, Yokota S. Flow cytometric chemosensitivity assay using JC1, a sensor of mitochondrial transmembrane potential, in acute leukemia. Cancer Chemother Pharmacol 2013;72(6): 1335-1342.
22. Annunziata CM, Bates SE. PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biol Rep 2010;2.
23. Shen Z, Huhn S. PTEN sumo-wrestles human RAD52 to mystery land. Cell Cycle 2013;12(23):3585.
24. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, Kiura K. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2013;11(2): 140-148.
25. Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S, Mufti GJ. Microsatellite instability induced mutations in DNA repair genes Ct IP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 2013;98(9): 1397-1406.
26. Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D. Reduced transthyretin expression in sera of lung cancer. Cancer Sci 2007;98(10): 1617-1624. (Pubitemid 47308460)
27. Linkov F, Gu Y, Arslan AA, Liu M, Shore RE, Velikokhatnaya L, Koenig KL, Toniolo P, Marrangoni A, Yurkovetsky Z, Zeleniuch-Jacquotte A, Lokshin AE. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur Cytokine Netw 2009;20(1): 21-26.
28. Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, Lokshin AE, Siegfried JM. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol 2012;7(4): 698-708.
29. Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in Cancer. Front Oncol. 2013;3:290.
30. Wu T, Wang XJ, Tian W, Jaramillo MC, Lau A, Zhang DD. Poly(ADP-ribose) polymerase-1 modulatesNrf2-dependent transcription. Free Radic Biol Med 2013;67C: 69-80.
31. Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP.Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer. 2010;9:45.
32. Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin TV, Kalinichenko VV. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras. Oncogene 2013. [Epub ahead of print]
33. Ausborn NL, Le QT, Bradley JD, Choy H, Dicker AP, Saha D, Simko J, Story MD, Torossian A, Lu B. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2012;83(4):e453-464.
34. Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S, Bubici C. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene 2013;32(36): 4231-4242.
35. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999;274(33): 22932-22940.
36. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13(10): 3033-3042. (Pubitemid 46849580)
37. Lapucci A, Pittelli M, Rapizzi E, Felici R, Moroni F, Chiarugi A. Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription. Mol Pharmacol 2011;79(6): 932-940.
38. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40(4): 1117-1123. (Pubitemid 32108606)
39. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58(23): 5315-5320. (Pubitemid 28551107)
40. Suchy SL, Landreneau RJ, Schuchert MJ, Wang D, Ervin PR, Jr., Brower SL. Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer. Cancer Biol Ther 2013;14(1): 39-44.